About Orna
Orna is a company based in Cambridge (United States) founded in 2020 by Alexander Wesselhoeft.. Orna has raised $201 million across 2 funding rounds from investors including Novartis, Merck and Kite Pharma. The company has 113 employees as of December 31, 2022. Orna has completed 1 acquisition, including ReNAgade. Orna offers products and services including oRNA, panCAR, and LNP Delivery. Orna operates in a competitive market with competitors including Dicerna Pharmaceuticals, OliX Pharmaceuticals, Envisagenics, Rznomics and Arcturus Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 113 as on 31 Dec, 2022
- Founders Alexander Wesselhoeft
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Orna Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orna
Orna offers a comprehensive portfolio of products and services, including oRNA, panCAR, and LNP Delivery. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineered circular RNA for enhanced protein expression in disease treatment.
In vivo system for cancer cell therapy without preconditioning.
Lipid nanoparticles for targeted RNA delivery beyond the liver.
Unlock access to complete
Unlock access to complete
Funding Insights of Orna
Orna has successfully raised a total of $201M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $121 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $121.0M
-
First Round
First Round
(24 Feb 2021)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2022 | Amount | Series B - Orna | Valuation | Merck | |
| Feb, 2021 | Amount | Series A - Orna | Valuation | MPM Capital , Taiho Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Orna
Orna has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Merck and Kite Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Taiho Ventures is focused on investing in global biotech ventures.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Orna
Orna has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ReNAgade. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
RNA-based medicines are developed for treating multiple diseases.
|
2021 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Orna
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Orna Comparisons
Competitors of Orna
Orna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Dicerna Pharmaceuticals, OliX Pharmaceuticals, Envisagenics, Rznomics and Arcturus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drugs are developed using RNA interference technology platform.
|
|
| domain | founded_year | HQ Location |
RNAi therapeutics are developed for dermal, ophthalmic, and pulmonary diseases.
|
|
| domain | founded_year | HQ Location |
RNA splicing therapeutics are discovered and developed through AI-driven biotechnology.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology
|
|
| domain | founded_year | HQ Location |
RNAi technologies are developed for treating rare orphan diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Orna
Frequently Asked Questions about Orna
When was Orna founded?
Orna was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Where is Orna located?
Orna is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Orna?
Tom Barnes is the current CEO of Orna.
Is Orna a funded company?
Orna is a funded company, having raised a total of $201M across 2 funding rounds to date. The company's 1st funding round was a Series A of $80M, raised on Feb 24, 2021.
How many employees does Orna have?
As of Dec 31, 2022, the latest employee count at Orna is 113.
What does Orna do?
Orna was founded in 2020 in Cambridge, United States, within the biotechnology sector focused on RNA therapeutics. Purification methods, IRES technology for protein expression, and lipid nanoparticle formulations are developed by the company. RNA viruses and enzymes are utilized to enable production, delivery, and gene expression in the human body. Therapeutics targeting cancer, autoimmune diseases, regenerative medicine, and genetic disorders are being advanced.
Who are the top competitors of Orna?
Orna's top competitors include Arcturus Therapeutics, Dicerna Pharmaceuticals and OliX Pharmaceuticals.
What products or services does Orna offer?
Orna offers oRNA, panCAR, and LNP Delivery.
How many acquisitions has Orna made?
Orna has made 1 acquisition, including ReNAgade.
Who are Orna's investors?
Orna has 10 investors. Key investors include Novartis, Merck, Kite Pharma, Bristol-Myers Squibb, and Turmeric Acquisition Corp.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.